Revenue swung from $12.4M to $1.6M over the period while gross margin fell from 13.4% to negative 9.8% and operating margins remained deeply negative, suggesting the top line and cost structure have not yet stabilized.
DataMEDS AI, Inc. (MEDS) annual income statement — 3-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 |
|---|
| Sales/Revenue | 7.68M | 23.34M | 18.13M | 0 |
| Revenue Growth % | -77.47% | 28.73% | - | - |
| Cost of Goods Sold | 17.87M | 32.98M | 16.36M | 0 |
| COGS % of Revenue | - | 141.3% | 90.25% | - |
| Gross Profit | -10.19M | -9.64M | 1.77M | 0 |
| Gross Margin % | -132.74% | -41.3% | 9.75% | - |
| Gross Profit Growth % | - | -645.32% | - | - |
| Operating Expenses | 19.34M | 71.56M | 7.91M | 2.88M |
| OpEx % of Revenue | - | 306.61% | 43.65% | - |
| Selling, General & Admin | 20.59M | 71.56M | 6.8M | 2.88M |
| SG&A % of Revenue | - | 306.61% | 37.5% | - |
| Research & Development | 0 | 0 | 0 | 375 |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | -643.17K | 0 | 1.11M | -375 |
| Operating Income | -29.53M | -81.19M | -6.15M | -2.88M |
| Operating Margin % | -384.58% | -347.91% | -33.9% | - |
| Operating Income Growth % | - | -1221.29% | -113.33% | - |
| EBITDA | -27.66M | -77.98M | -5.03M | -2.88M |
| EBITDA Margin % | -360.2% | -334.15% | -27.75% | - |
| EBITDA Growth % | 59.96% | -1450.23% | -74.63% | - |
| D&A (Non-Cash Add-back) | 1.87M | 3.21M | 1.11M | 0 |
| EBIT | -29.21M | -96.69M | -6.02M | -2.88M |
| Net Interest Income | -6.76M | -4.58M | -831.47K | -15.08K |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 6.76M | 4.58M | 831.47K | 15.08K |
| Other Income/Expense | -13.89M | -20.08M | -711.09K | -15.08K |
| Pretax Income | -43.42M | -101.27M | -6.86M | -2.9M |
| Pretax Margin % | -565.48% | -433.95% | -37.82% | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -43.37M | -101.27M | -6.86M | -2.9M |
| Net Margin % | -564.77% | -433.95% | -37.82% | - |
| Net Income Growth % | 44.22% | -1377.12% | -136.77% | - |
| Net Income (Continuing) | -43.42M | -101.27M | -6.86M | -2.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 1.87M | 0 | 0 | 0 |
| EPS (Diluted) | -10.95 | -71.50 | -6.50 | -3.00 |
| EPS Growth % | 66.3% | -1000% | -116.67% | - |
| EPS (Basic) | - | -71.50 | -6.50 | -3.00 |
| Diluted Shares Outstanding | 3.96M | 1.42M | 1.04M | 894.4K |
| Basic Shares Outstanding | 3.21M | 1.42M | 1.04M | 894.4K |
| Dividend Payout Ratio | - | - | - | - |
Quick answers to the most common questions about buying MEDS stock.
For fiscal year 2025, DataMEDS AI, Inc. (MEDS) reported total revenue of $23.3M.
DataMEDS AI, Inc. (MEDS) reported a net loss of $101.3M for the fiscal year ending 2025.
DataMEDS AI, Inc. (MEDS) reported an operating income of $-81.2M, resulting in an operating profit margin of -347.9%. This margin reflects the operational efficiency of the business before interest and taxes.
DataMEDS AI, Inc. (MEDS) generated $-9.6M in gross profit for the year, representing a gross profit margin of -41.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses and volatile revenue
Metrics are mathematically derived from official filings.
Revenue Volatility Masks Weak Underlying Demand
Based on reported quarterly figures, DataMEDS AI's revenue swung from $12.4M in 2024Q4 to $1.6M in 2026Q1, a contraction that suggests the top line has not yet found a durable base.
The sequence shows revenue falling roughly 87 percent over five quarters, with year-over-year declines of 85 to 87 percent in several recent periods. The single positive quarter in 2026Q3 at $2.7M does not establish a recovery trend, and investors should monitor whether this rebound persists. Without a clear driver breakdown, the reported figures do not allow separation of volume, pricing, or acquisition effects.
Gross Margins Collapse Into Negative Territory
As reported in the income statement, gross margin moved from 13.4% in 2024Q2 to negative 9.8% in 2026Q2, indicating that direct costs have at times exceeded revenue.
Gross margin has oscillated sharply, including a negative quarter in 2025Q4 where COGS of $11.9M against $1.7M of revenue produced a gross loss of $10.3M. This pattern suggests the company may lack pricing power or has cost structures that do not scale with revenue. The volatility warrants further investigation into whether the cost base is fixed or contains one-time charges.
Operating Losses Persist Despite Scale Changes
Based on EDBL-style reported figures, DataMEDS AI posted operating losses in every one of the ten quarters, with SG&A ranging from $1.8M to $31.2M against revenue that never exceeded $12.4M.
SG&A has swung dramatically, including spikes to $31.0M in 2025Q3 and $31.2M in 2025Q1, which far exceed revenue in those periods and drove operating margins below negative 100 percent. This suggests overhead is not scaling with the business and may reflect discrete charges, though the data does not disclose their nature. Operating leverage is therefore negative in practice, and the company has not demonstrated an efficient cost base.
Net Income Diverges Sharply From Operations
According to the reported statements, net income of positive $10.6M in 2026Q3 stands against an operating loss of $3.4M, a gap that calls the quality of the reported profit into question.
A profitable net result alongside a material operating loss implies non-operating gains, tax effects, or other items not disclosed in the supplied data, and these cannot be verified from the figures provided. The EPS swing from negative 7.13 to positive 2.67 across adjacent quarters further suggests the bottom line is driven by items unrelated to core activity. Investors should treat the 2026Q3 profit as non-recurring until the drivers are explained.
Bear Case Centers on Chronic Cash Burn Risk
Based on reported figures, stock-based compensation of $25.7M in 2025Q3 and $27.8M in 2025Q1 represents a large share of operating costs, which raises the question of how much of the expense base is non-cash.
Short-seller scrutiny would likely focus on the recurring operating losses, the negative gross margins, and the dependence on large equity-based compensation that dilutes existing holders, with EPS falling to negative 31.00 in 2025Q1. Peer comparison reinforces the concern, since the healthcare services peer HCSG reports a positive operating margin of 2.6 percent while MEDS has operated at a loss throughout the period. The analysis does not establish how these losses will be financed going forward, so the sustainability of the current cost structure warrants further investigation.